Thank on hello Christian, to you, the and call. everyone
Next slide, please.
the is now programs of of heard the the Three and STAR-T clinical and clinical FDA you is for seven comprises United theme the including XXXX pilot randomized COVID-XX use granted study, priority And trials, STAR and our with shock, randomized focus. including COVID-XX. Registry As programs, study executed patients the one the liver in already, streamlined the registry study. three and programs includes in septic STAR-D study clinical under also pilot in top and international the Use updated the execution randomized and clinical CytoSorbents in for trials, Authorization respectively. our CytoSorb of our executing with in patients the plan COSMOS in HepOnFire CytoSorb four acute-on-chronic three refractory Accordingly, Registry, are Emergency registries PROCYSS that remaining Europe, failure are States, therapy two and
with note the As world, to we’re personnel shortages fatigue we engaging pandemic. continue they aftermath institutions and that around in the of the with struggle
encouraged will in we’re participation and month Care high Medicine, continue and levels additional that on in numerous published extending However, Symposium our year, with EuroELSO International clinical at CytoSorb observations including survival There COVID-XX the Brussels, results accepted from May. showing Emergency the last in to potentially in CTC This valuable of clinical be we Conference original and use interest follow-up to in London benefits. the on the later Registry International and in this presented presented the COVID-XX of data be will of data high data will from abstracts that programs. for see Intensive readouts XXXX, the now
publish clinical final year If data largest readouts to resources trials, accepted may completed results potential this XXXX. later international XXX even also We drug later year, have ever European first in top the Cardiology. early enrollment FDA also ever the of focus STAR-D be this XXXX also the early will have in the removal in conference this August. is have Later programs. plan or abstract intend in we from Society Registry to later results cardiovascular the this submit discontinued STAR first priority the To in CTC patients the year. and presented following our our in to STAR-T there antithrombotic and we we vivo We to Registry, our
focused allow will resources our the clinical X-AKI trial, which REFRESH team on the now U.S. programs. be all STAR First, to
of discontinued independent device Germany, randomized evidence noted citation studies. by be the STAR-T single-arm evaluating the that concerns small Pfizer superseded We these the clinical studies, urgent studies, and no by in higher in both safety the much surgery each generated important UK level of three both also they that DSMB were now study. of It’s the to there in our note U.S. that will intraoperative three the confirmed will were as use any as cardiac ticagrelor with patients be in undergoing by pivotal in removal,
Next slide, please.
trials. priority the STAR-D evaluating in study have rivaroxaban Moving recruiting top programs, namely use actually device during patients. the two of patients STAR-T studies the in despite drugs these STAR-T participate on very fatigue left Both cardiac that station them, in with these urgent they at the both and on The or the to the high have our U.S. they and selected, actively the ATR studies have most of institutions. studies FDA the in majority of of pandemic study. are either studies STAR-D for the apixaban in is been now over ticagrelor now XX%, or sites surgery participating Enthusiasm will noting
by across board the the to Based on times the shortages STAR-D are and synergies faster U.S. the seeing done the study. the them However, start-up are we’re identical institutions. work site moving at real, the up start already in staff design, STAR-T leveraging study
identical addition highlighted are by paths executional to the milestones design, major have identical in Importantly, below. the three table both that studies in listed
of safety first XX% trigger patients enrollment review. The DSMB milestone the of first is that the will the
study interim but review, triggered of completion course, finally, study And unless, after analysis started been milestone the importantly, of represents analysis. enrollment represents trial. second of The and efficacy the of second the study the the DSMB the the has with third XX% for the XXX% at are interim also milestone the enrolled patients previously is safety in the
hit months at with multiple is this within completed projected summer, study for to specifically, enrollment number to STAR-T of Now enrolling XX actively is milestone studies, be sites from and expected two today. the one is the
STAR-D, is actively For multiple at it sites. also recruiting
we project early of the pace Investigator Later study. believe, both studies, right however, month, Summit, enrollment it’s patient this significant months XX believe study earnings in to milestones be entered will calls have all these excitement sites introduce a within to the listed participating the the the are that our of plan of studies. in We for the studies, making will completed levels will However, which following across all progress for major enrollment we future the they the do to first too And progress XX in both below. studies we both now study communicate event according to the the study. towards
please. slide, Next
to programs, five on Moving we have table. on listed non-FDA now programs this clinical our
the the with as Registry results on believe CTC We inform critically enrollment noted been will presentations ECMO. completed has and around and publications at previously, multiple data life also has Registry. use support including database for with the of now, there this First, severe final will with the The COVID-XX, ill international and patients requiring world patients the later platform this be ECMO, including COVID-XX, for failure. and, suffering this locked XXX CTC conferences respiratory beyond of single-use year, increase readouts
now randomized Germany. clinical patients study PROCYSS multiple septic enrolling is with actively the in Next, at shock refractory sites in
and in will interim this which the surgery are tradition. place and and different expand and analysis, after to in to hoping And and end Germany. removal continue in of have around Registry of be more second be year. on triggered study in will at patients once specifically is UK number Europe bring sites, and study, the have data enrolled STAR quarter. included we of the The the countries readouts anticipate for the that we sites international we’re enroll, strategy patients, continue registry to the sufficient This The cardiac next ongoing. continue those expect next be anti-thrombotic all we and to that take actively data to to we will We half milestone patients to readouts the is will be enrolling there
acute half beginning the and year. the the Finally, and the registry approvals both and applications care Registry study we We begin Germany, all-inclusive and have year, with half critical to of both sites. first in HepOnFire also COSMOS patients are received pilot this first among that anticipate will failure activate begin in enrollment the in COSMOS enrollment in will our of Registry this liver
please. slide, Next
have focused our our execution we summary, resources programs. ensure STAR-D to priority FDA disciplined of top and STAR-T in So
sites with both engage are levels and staffing struggling they U.S. pandemic but on Both for institutions see to fatigue we we the As of Europe, in studies. our high is and continue enrolling in actively targeting study now are clinical with programs randomized PROCYSS, recruiting FDA excitement still milestone Germany. at in STAR-T our multiple sites at lead, we that note in care the first priority shortages, top summer. this multiple critical actively
data over and COSMOS turn like both Registry platforms with real-world Registry our Phil. readouts STAR critical would we be will for Phil? And finally, both that, they evidence data the in the important and CTC generation to back making progress, good and and has as noted I it are very in represent XXXX. the enrollment, surgery supporting future in are to care. cardiac before, having multiple As completed they International And
